Lyra Therapeutics, Inc. Common Stock (LYRA) Stock Price

LYRAStock

$0.01−21.95%52W

Market Cap$17,748.82

P/E—

PEG Ratio—

Div yield—

Beta0.74

LYRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-110.76%

Price vs S&P 500 (4W)-100.97%

VGM Score12.04

Book Value / Share (Quarterly)$1.00

P/TBV (Annual)1.87x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-33.61%

Cash Flow / Share (Quarterly)$-16.32

Price vs S&P 500 (YTD)-110.49%

Net Profit Margin (TTM)-7266.08%

EPS (TTM)$-19.31

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-19.31

Revenue Growth (5Y)4.35%

EPS (Annual)$-18.62

ROI (Annual)-805.89%

Net Profit Margin (5Y Avg)-7289.66%

Cash / Share (Quarterly)$8.95

Revenue Growth QoQ (YoY)-96.65%

ROA (Last FY)-80.09%

Revenue Growth TTM (YoY)-74.05%

EBITD / Share (TTM)$-19.69

ROE (5Y Avg)-220.19%

Operating Margin (TTM)-7794.47%

Cash Flow / Share (Annual)$-16.32

P/B Ratio0.27x

P/B Ratio (Quarterly)8.98x

Net Income / Employee (Annual)$-1,071,100

EV / Revenue (TTM)-38.82x

ROA (TTM)-61.30%

EPS Incl Extra (Annual)$-18.62

Current Ratio (Annual)1.71x

Quick Ratio (Quarterly)1.67x

3-Month Avg Trading Volume0.01M

52-Week Price Return-21.95%

Revenue / Employee (TTM)$14,700

Tangible BV / Share (Quarterly)$1.70

P/S Ratio (Annual)1.11x

Asset Turnover (Annual)0.01x

52-Week High$8.75

Operating Margin (5Y Avg)-7513.04%

EPS Excl Extra (Annual)$-18.62

CapEx CAGR (5Y)-42.08%

26-Week Price Return-99.51%

Quick Ratio (Annual)1.67x

13-Week Price Return-98.65%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.71x

Enterprise Value$-15.45M

Revenue / Share Growth (5Y)63.77%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$14,700

Pretax Margin (Annual)-7263.32%

Cash / Share (Annual)$8.95

3-Month Return Std Dev4742.97%

Net Income / Employee (TTM)$-1,071,100

ROE (Last FY)-805.89%

EPS Basic Excl Extra (Annual)$-18.62

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-19.31

ROI (TTM)-411.98%

P/S Ratio (TTM)1.11x

Pretax Margin (5Y Avg)-7287.69%

Revenue / Share (Annual)$0.26

Tangible BV / Share (Annual)$2.54

Price vs S&P 500 (52W)-31.06%

Year-to-Date Return-99.68%

5-Day Price Return-71.83%

EPS Normalized (Annual)$-18.62

ROA (5Y Avg)-78.88%

Net Profit Margin (Annual)-7266.08%

Month-to-Date Return-97.89%

Cash Flow / Share (TTM)$-1.41

EBITD / Share (Annual)$-19.67

Operating Margin (Annual)-7794.47%

ROI (5Y Avg)-220.19%

EPS Basic Excl Extra (TTM)$-19.31

P/TBV (Quarterly)1.80x

P/B Ratio (Annual)1.17x

Pretax Margin (TTM)-7263.32%

Book Value / Share (Annual)$8.85

Price vs S&P 500 (13W)-101.44%

Beta0.74x

Revenue / Share (TTM)$0.22

ROE (TTM)-411.98%

52-Week Low$0.00

gGradeF

mGradeF

vgmGradeF

LYRA Earnings Surprise History

Q4 24-7.09est. -6.50

Q1 25-6.50est. -6.83

Q2 25-5.22est. -4.78

Q3 25-3.40est. -4.07

LYRA Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

2.17

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
LYRALyra Therapeutics, Inc. Common Stock	—	F	F	$0.01
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16

About Lyra Therapeutics, Inc. Common Stock

Lyra Therapeutics is a clinical-stage biopharmaceutical company developing innovative drug delivery solutions for ear, nose, and throat (ENT) diseases. The company's lead product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices administered in brief, non-invasive in-office procedures to deliver continuous therapy directly to the sinonasal passages for chronic rhinosinusitis. This localized delivery approach aims to provide therapeutic benefits while minimizing systemic exposure.